We’re excited to join the @Nasdaq family! Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL
Candel Therapeutics appoints Diem Nguyen, Ph.D., M.B.A., to Board of Directors
https://www.businesswire.com/news/home/20210715005303/en/Candel-Therapeutics-Appoints-Diem-Nguyen-Ph.D.-M.B.A.-to-Its-Board-of-Directors
The results of this first-in-human study of CAN-3110 demonstrate a median overall survival that was substantially longer than the six to nine months typically observed in recurrent high-grade glioma as well as a favorable safety profile.
https://www.businesswire.com/news/home/20210604005138/en/Candel-Therapeutics-Announces-Data-from-Phase-1-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-2021-American-Society-of-Clinical-Onc…
Candel Therapeutics at the Jefferies Virtual Healthcare Conference 2021
Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Exec…
Carrie Cox joins the Candel team and lead our Board of Directors
We are delighted to have Carrie Cox join the Candel team and lead our Board of Directors. Her strategic insights will be key as we advance our late stage pipeline of agents with the potential to bec…
